XTRA:MRKPharmaceuticals
Merck KGaA (XTRA:MRK) Could Be 5% Undervalued Following Its BioReliance Facility Opening
Merck KGaA (XTRA:MRK) has opened a new €25 million, 2,000 square meter BioReliance testing facility at its Darmstadt headquarters, widening access to biologics release and stability testing for European biopharmaceutical clients.
See our latest analysis for Merck KGaA.
Merck KGaA’s latest facility opening comes after a period where the stock has climbed, with a 90 day share price return of 15.95% and a 1 year total shareholder return of 25.71%. However, longer term five year total shareholder...